Traws Pharma, Inc. financial data

Symbol
TRAW on Nasdaq
Location
12 Penns Trail, Newtown, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Onconova Therapeutics, Inc. (to 4/1/2024), ONCONOVA THERAPEUTICS INC (to 5/26/2009)
Latest financial report
10-Q - Q2 2024 - Aug 15, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 226 % -49.3%
Operating Margin -61.1K % -524%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.3M shares +20.6%
Common Stock, Shares, Outstanding 25.3M shares +20.6%
Entity Public Float 24.6M USD -10.5%
Common Stock, Value, Issued 253K USD +20.5%
Weighted Average Number of Shares Outstanding, Basic 25.3M shares +20.6%
Weighted Average Number of Shares Outstanding, Diluted 25.3M shares +20.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 226K USD 0%
Research and Development Expense 9.26M USD -31.3%
General and Administrative Expense 10.1M USD +19.6%
Operating Income (Loss) -138M USD -524%
Net Income (Loss) Attributable to Parent -123M USD -2797%
Earnings Per Share, Basic -5.53 USD/shares -453%
Earnings Per Share, Diluted -5.53 USD/shares -453%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 20.6M USD -46.6%
Other Assets, Current 583K USD +121%
Assets, Current 18.7M USD -38.7%
Property, Plant and Equipment, Net 14K USD -17.6%
Other Assets, Noncurrent 1K USD 0%
Assets 18.7M USD -38.7%
Accounts Payable, Current 6.17M USD +21.8%
Employee-related Liabilities, Current 390K USD -47.4%
Accrued Liabilities, Current 3.51M USD +4.16%
Contract with Customer, Liability, Current 227K USD +0.44%
Liabilities, Current 9.91M USD +14.4%
Contract with Customer, Liability, Noncurrent 2.68M USD -7.82%
Liabilities 12.6M USD +8.79%
Accumulated Other Comprehensive Income (Loss), Net of Tax -33K USD -17.9%
Retained Earnings (Accumulated Deficit) -611M USD -28.9%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -106M USD -658%
Liabilities and Equity 18.7M USD -38.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.42M USD +2.62%
Common Stock, Shares Authorized 125M shares 0%
Common Stock, Shares, Issued 25.3M shares +20.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.43M USD +2.34%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.9M USD -43.2%
Deferred Tax Assets, Valuation Allowance 174M USD +2.44%
Deferred Tax Assets, Gross 174M USD +2.44%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -123M USD -2797%
Property, Plant and Equipment, Gross 84K USD +20%
Deferred Tax Assets, Operating Loss Carryforwards 74M USD +0.87%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 4K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.41M USD +14.5%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%